AlphAIAlphAI — Financial news for AI agents
patch.comSEP 212 min read$ABT

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

Original reporting
patch.com
Published Sep 21, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula — source image
Source · patch.com
Decision brief

The 30-second read

$ABTBearishHigh
01

Why it matters

The $385M payout represents a significant legal expense and may trigger further regulatory reviews of Abbott's manufacturing processes.

02

Market read

The settlement introduces a material liability for Abbott, likely influencing its stock price and prompting broader sector risk assessment.

03

What to watch

Abbott's recent FDA consent decree and product recalls could compound risk, but the company may benefit from long‑term demand for its broader portfolio.

Relevance 8/10Novelty 8/10Timing: Sep 21 2026 (date of settlement announcement)

Background

Abbott Laboratories faced False Claims Act allegations for misrepresenting infant formula safety, leading to a multi‑state settlement.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott Laboratories agreed to pay a $385M settlement over false claims related to its infant formula.

Expected impact

Potential short-term downside of 3‑5% as investors reassess liability exposure.

Evidence & confidence

Large, newly disclosed settlement amount for a major U.S. health‑care company is material and likely to affect valuation.

Market effects

Sector

May raise scrutiny on other infant‑formula manufacturers and health‑care suppliers.

Regional

Potential ripple effect on U.S. consumer‑health stocks and related Medicaid suppliers.

Global

Highlights regulatory risk for multinational nutrition companies worldwide.

Counterpoint

What could challenge this read

If the settlement is fully covered by insurance and does not affect cash flow, the stock may be oversold.

Key entities

  • Public Official
    Rob Bonta

    California Attorney General announcing the settlement.

  • Government Program
    U.S. Department of Agriculture (USDA) WIC program

    Major purchaser of infant formula affected by the settlement.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 21
$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

wral.com2 min
SEP 20
$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

foodsafetynews.com4 min
SEP 20
$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

gjsentinel.com2 min
SEP 19
$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

wpdh.com2 min
SEP 18
$ABTHighAI 9/10

Why Wall Street Is Becoming Even More Bullish About This Dividend King

Abbott Laboratories (NYSE: ABT) reported Q2 2026 sales of $12.6B, up 13%, and raised its full-year adjusted EPS forecast to $5.45-$5.60. Analysts are bullish, citing growth in its Medical Devices segment and recent acquisitions. The stock has 21 'buy' ratings with target prices up to $143. Abbott's dividend history and growth prospects are key attractions for investors.

theglobeandmail.com3 min